Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    iCMLf Forum 2019: Webstreams now available

    Tim Hughes 2019 iCMLf ForumWebstreams of the presentations from the iCMLf Forum for Physicians from Emerging Regions 2019 presented in partnership with The Max Foundation are now available to view. This year's Forum focused again on overcoming challenges in managing CML, featuring practical discussions with CML experts. CML experts gave the global perspective followed by local emerging regions perspectives from The Russian Federation and Brazil and a discussion with the audience. 

    Topics include:

    1. Perspectives on the future of CML 
      Professor Jorge Cortes (USA)
    2. Modelling responses when testing less frequently than monthly
      Associate Professor Susan Branford (Australia) 
    3. Re-evaluating TKI use in pregnancy in 2019
      Dr Ekaterina Chelysheva (Russian Federation) and Dr Carla Boquimpani (Brazil)

    Click on the presentations below to view the webstreams and see the slides.
    (We are very grateful for the support of Brandcast media to produce these web streams) 




    Jorge Cortes 2019 iCMLf Forum

    Professor Jorge Cortes
    Augusta, GA, USA

    Perspectives on the Future of CML

    Topics include: Survival in early chronic phase CML; improving long-term outcomes; outcomes from first-line TKI's; evolution of CML; recurrence-free survival; treatment recommendation by LEAP; treatment-free remission (TFR); disease eradication in CML; Asciminib add-on to first-line TKI's; quality of life on TFR; new TKI's.




    Susan Branford 2019 iCMLf Forum

    Associate Professor Susan Branford
    Adelaide, Australia

    Modelling responses when testing less frequently than monthly after stopping therapy

    Topics include: Molecular monitoring of BCR-ABL 1 transcripts; sustained deep molecular response is a prerequisite for discontinuation; frequency of monitoring; molecular monitoring after TKI discontinuation; knowns from discontinuation studies; monitoring strategies in the first 12 months.




    Ekaterina Chelysheva 2019 iCMLf Forum

    Dr Ekaterina Chelysheva
    Moscow, Russian Federation

    Re-evaluating TKI use in Pregnancy in 2019

    Topics include: Leukemia in pregnancy - to treat or not to treat?; crucial periods in prenatal development; abnormalities on Imatinib in literature; congenital malformations and use of TKI's; CML status and pregnancy; three case studies; CML pregnancy registry; CML and pregnancy - the Russian experience; LET scheme.




    Carla Boquimpani 2019 iCMLf Forum

    Dr Carla Boquimpani
    Rio de Janeiro, Brazil

    Re-evaluating TKI use in Pregnancy in 2019

    Topics include: Epidemiology in pregnancy in CML patients; four different scenarios in CML and pregnancy: 1. CML diagnosis during pregnancy  2. unexpected pregnancy during CML treatment  3. partner pregnancy of CML patient  4. CML patient wishing to become pregnant; CML in the Brazilian scenario; TKI's and pregnancy; case reports.